Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRISTOL MYERS SQUIBB COBMY · Entity 1662 | Director · EVP, CSO & President R&D | June 03, 2013 | June 05, 2013 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRISTOL MYERS SQUIBB CO
Report date June 03, 2013 · Filed June 05, 2013
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.10 par valueSEC Table I · non-derivative | Direct | 148,221 |
Ending reported balance
After 2013-06-03 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2013-06-03 · Exercise / conversion · Acquired 98,875 · Balance 231,868 Row 2 · 2013-06-03 · Sale · Disposed 83,647 · Balance 148,221 F1: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $47.83 to $48.62, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price. |
| Executive Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.01 · Expires 2017-03-05 | Direct | 25,000 |
Reported balance
After 2013-06-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2013-06-03 · Exercise / conversion · Disposed 98,875 · Balance 25,000 F3: Twenty-five percent of the stock option award vested on each of the first, second, third, and fourth anniversaries of the grant date, which was March 6, 2007. |
| Common Stock, $0.10 par valueSEC Table I · non-derivative | IndirectBy BMY Savings & Investment Program | 1,628.06 |
Reported balance
Holding disclosure · report date 2013-06-03 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,628.06 F2: Based on a plan statement as of the end of the most recent fiscal quarter. |
| Common Stock, $0.10 par valueSEC Table I · non-derivative | IndirectBy C. Elliott Sigal 2012 Irrevocable Trust | 18,180 |
Reported balance
Holding disclosure · report date 2013-06-03 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 18,180 |
| Common Stock, $0.10 par valueSEC Table I · non-derivative | IndirectBy Ruth L. Sigal Irrevocable Trust | 18,180 |
Reported balance
Holding disclosure · report date 2013-06-03 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 18,180 |
| Common Stock, $0.10 par valueSEC Table I · non-derivative | IndirectBy Sigal Family Investments, LLC | 9,091 |
Reported balance
Holding disclosure · report date 2013-06-03 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 9,091 |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported reflects the weighted average sales price. The shares were sold in multiple transactions at prices ranging from $47.83 to $48.62, inclusive. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
F2: Based on a plan statement as of the end of the most recent fiscal quarter.
F3: Twenty-five percent of the stock option award vested on each of the first, second, third, and fourth anniversaries of the grant date, which was March 6, 2007.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Mead Johnson Nutrition Co
Report date June 15, 2017 · Filed June 15, 2017
Section 16 reporting ended · disclosed 2017-06-15. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2017-06-15 transaction · row 1
1 source rowRow 1 · 2017-06-15 · Disposition to issuer · Disposed 13,721 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated February 10, 2017, by and among Mead Johnson Nutrition Company ("MJN"), Reckitt Benckiser Group plc, and Marigold Merger Sub, Inc. (the "Merger Agreement"), at the effective time of the merger, each share of MJN common stock held by the reporting person was converted into the right to receive a cash payment equal to $90.00 per share. |
| Common StockSEC Table I · non-derivative | IndirectBy Sigal Family Investments, LLC | 0 |
Reported balance
After 2017-06-15 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2017-06-15 · Disposition to issuer · Disposed 2,590 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated February 10, 2017, by and among Mead Johnson Nutrition Company ("MJN"), Reckitt Benckiser Group plc, and Marigold Merger Sub, Inc. (the "Merger Agreement"), at the effective time of the merger, each share of MJN common stock held by the reporting person was converted into the right to receive a cash payment equal to $90.00 per share. |
| Common StockSEC Table I · non-derivative | IndirectBy the C. Elliott Sigal 2012 Irrevocable Trust | 0 |
Reported balance
After 2017-06-15 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2017-06-15 · Disposition to issuer · Disposed 5,180 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated February 10, 2017, by and among Mead Johnson Nutrition Company ("MJN"), Reckitt Benckiser Group plc, and Marigold Merger Sub, Inc. (the "Merger Agreement"), at the effective time of the merger, each share of MJN common stock held by the reporting person was converted into the right to receive a cash payment equal to $90.00 per share. |
| Common StockSEC Table I · non-derivative | IndirectBy the Ruth L. Sigal 2012 Irrevocable Trust | 0 |
Reported balance
After 2017-06-15 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2017-06-15 · Disposition to issuer · Disposed 5,180 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated February 10, 2017, by and among Mead Johnson Nutrition Company ("MJN"), Reckitt Benckiser Group plc, and Marigold Merger Sub, Inc. (the "Merger Agreement"), at the effective time of the merger, each share of MJN common stock held by the reporting person was converted into the right to receive a cash payment equal to $90.00 per share. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2017-06-15 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2017-06-15 · Disposition to issuer · Disposed 1,709 · Balance 0 F2: Each restricted stock unit ("RSU") represents the contingent right to receive one share of common stock. F3: This RSU was originally scheduled to vest on February 28, 2018. Pursuant to the Merger Agreement, at the effective time of the merger, the RSUs held by the reporting person vested and were cancelled in exchange for a lump-sum cash payment equal to the product of (i) the number of shares of common stock subject to such RSU immediately prior to the effective time of the merger and (ii) $90.00 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated February 10, 2017, by and among Mead Johnson Nutrition Company ("MJN"), Reckitt Benckiser Group plc, and Marigold Merger Sub, Inc. (the "Merger Agreement"), at the effective time of the merger, each share of MJN common stock held by the reporting person was converted into the right to receive a cash payment equal to $90.00 per share.
F2: Each restricted stock unit ("RSU") represents the contingent right to receive one share of common stock.
F3: This RSU was originally scheduled to vest on February 28, 2018. Pursuant to the Merger Agreement, at the effective time of the merger, the RSUs held by the reporting person vested and were cancelled in exchange for a lump-sum cash payment equal to the product of (i) the number of shares of common stock subject to such RSU immediately prior to the effective time of the merger and (ii) $90.00 per share.
Spark Therapeutics, Inc.
Report date December 17, 2019 · Filed December 17, 2019
Section 16 reporting ended · disclosed 2019-12-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 1
1 source rowRow 1 · 2019-12-17 · Other · Disposed 14,214 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $81.53 · Expires 2028-05-29 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-12-17 · Disposition to issuer · Disposed 4,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.93 · Expires 2027-05-30 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-12-17 · Disposition to issuer · Disposed 4,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.22 · Expires 2026-05-31 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-12-17 · Disposition to issuer · Disposed 6,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.45 · Expires 2024-08-11 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-12-17 · Disposition to issuer · Disposed 17,203 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.45 · Expires 2024-06-10 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-12-17 · Disposition to issuer · Disposed 25,786 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn.
F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 06, 2007 Filed Mar 8, 2007 22:18 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantExecutive Option (right to buy) · Derivative | 244,500 | $0.00 Strike: $27.01 | $0.00 |
DisclosureSEC source: 0000014272-07-000082 · sig684.xml · derivative · entry 4 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President PRI 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,500 Underlying: Common Stock, $0.10 par value · 244,500 shares Expires 2017-03-05 F5 · derivative.exercise_date: Option is not exercisable until the closing share price of common stock achieves a price of at least 15% above the option grant price and remains at that price for seven consecutive trading days. Option vests 25% of the shares annually, on a cumulative basis, commencing one year after the date of grant, but may not be exercised until the threshold is satisfied. Read SEC document |
| March 06, 2007 Filed Mar 8, 2007 22:18 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 1,052 | $27.01 | $28,414.52 |
DisclosureSEC source: 0000014272-07-000082 · sig684.xml · nonDerivative · entry 2 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President PRI 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,153 F3 · shares: Shares withheld for payment of taxes. F2 · balance_after: Includes unvested restricted stock awards. Read SEC document |
| March 06, 2007 Filed Mar 8, 2007 22:18 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantCommon Stock, $0.10 par value | 2,264 | $27.01 | $61,150.64 |
DisclosureSEC source: 0000014272-07-000082 · sig684.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President PRI 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,205 F1 · shares: Consists of shares earned as long-term performance awards under the 2002 Stock Incentive Plan. F2 · balance_after: Includes unvested restricted stock awards. Read SEC document |
| March 06, 2007 Filed May 10, 2007 21:20 UTC Amendment | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantRestricted Stock Units · Derivative | 20,625 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-07-000129 · sig703.xml · derivative · entry 5 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President PRI 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,625 Underlying: Common Stock, $0.10 par value · 20,625 shares Expires not disclosed F6 · derivative.exercise_price: This Form 4 is being amended to clarify that each restricted stock unit converts into one share of common stock upon vesting. F7 · derivative.exercise_date: One-third of the restricted stock units will vest on each of the third, fourth and fifth anniversaries of the grant date and be converted into shares of common stock. F7 · derivative.expiration_date: One-third of the restricted stock units will vest on each of the third, fourth and fifth anniversaries of the grant date and be converted into shares of common stock. Read SEC document |
| March 06, 2007 Filed May 10, 2007 21:20 UTC Amendment | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantExecutive Option (right to buy) · Derivative | 244,500 | $0.00 Strike: $27.01 | $0.00 |
DisclosureSEC source: 0000014272-07-000129 · sig703.xml · derivative · entry 4 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President PRI 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,500 Underlying: Common Stock, $0.10 par value · 244,500 shares Expires 2017-03-05 F5 · derivative.exercise_date: Option is not exercisable until the closing share price of common stock achieves a price of at least 15% above the option grant price and remains at that price for seven consecutive trading days. Option vests 25% of the shares annually, on a cumulative basis, commencing one year after the date of grant, but may not be exercised until the threshold is satisfied. Read SEC document |
| March 06, 2007 Filed May 10, 2007 21:20 UTC Amendment | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 1,052 | $27.01 | $28,414.52 |
DisclosureSEC source: 0000014272-07-000129 · sig703.xml · nonDerivative · entry 2 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President PRI 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,153 F3 · shares: Shares withheld for payment of taxes. F2 · balance_after: Includes unvested restricted stock awards. Read SEC document |
| March 06, 2007 Filed May 10, 2007 21:20 UTC Amendment | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantCommon Stock, $0.10 par value | 2,264 | $27.01 | $61,150.64 |
DisclosureSEC source: 0000014272-07-000129 · sig703.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President PRI 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,205 F1 · shares: Consists of shares earned as long-term performance awards under the 2002 Stock Incentive Plan. F2 · balance_after: Includes unvested restricted stock awards. Read SEC document |
| March 02, 2007 Filed Mar 6, 2007 19:53 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 979 | $26.42 | $25,865.18 |
DisclosureSEC source: 0000014272-07-000064 · sig665.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President PRI 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,941 F1 · kind: Shares withheld for payment of taxes upon vesting of restricted stock. F2 · balance_after: Includes shares of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date. Read SEC document |
| March 01, 2007 Filed Mar 2, 2007 21:42 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 3,038 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-07-000050 · sig659.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President PRI 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,920 F1 · kind: Shares withheld for payment of taxes upon vesting of restricted stock. F2 · balance_after: Includes shares of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date. Read SEC document |
| February 21, 2007 Filed Feb 23, 2007 20:52 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 1,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-07-000048 · sig658.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President PRI 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,958 F1 · kind: Shares withheld for payment of taxes upon vesting of restricted stock. F2 · balance_after: Includes shares of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date. Read SEC document |
| December 01, 2006 Filed Dec 4, 2006 19:39 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantExecutive Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $24.74 | $0.00 |
DisclosureSEC source: 0000014272-06-000231 · sig628.xml · derivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · EVP, CSO & President PRI 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock, $0.10 par value · 300,000 shares Expires 2016-11-30 F1 · derivative.exercise_date: Option is not exercisable until the closing share price of common stock achieves a price of at least 15% above the option grant price and remains at that price for seven consecutive trading days. Shares vest one-third per year, on a cumulative basis, on the third, fourth, and fifth anniversaries of the grant date. Read SEC document |
| November 01, 2006 Filed Nov 3, 2006 22:01 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 3,038 | $24.76 | $75,220.88 |
DisclosureSEC source: 0000014272-06-000215 · sig624.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · CSO & President PRI 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,108 F1 · shares: Shares withheld for payment of taxes upon vesting of restricted stock. F2 · balance_after: Includes shares of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date. Read SEC document |
| September 08, 2006 Filed Sep 12, 2006 20:38 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 3,038 | $22.96 | $69,752.48 |
DisclosureSEC source: 0000014272-06-000186 · sig597.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · CSO & President PRI 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 183,146 F1 · shares: Shares withheld for payment of taxes upon vesting of restricted stock. Read SEC document |
| March 07, 2006 Filed Mar 9, 2006 22:10 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantExecutive Option (right to buy) · Derivative | 95,795 | $0.00 Strike: $22.73 | $0.00 |
DisclosureSEC source: 0000014272-06-000103 · sig521.xml · derivative · entry 5 SIGAL ELLIOT · CIK 0001202294 · CSO & President PRI 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,795 Underlying: Common Stock, $0.10 par value · 95,795 shares Expires 2016-03-06 F5 · derivative.exercise_date: Option is not exercisable until the closing share price of common stock achieves a price of at least 15% above the option grant price and remains at that price for seven consecutive trading days. Option vests 25% of the shares annually, on a cumulative basis, commencing one year after the date of grant, but may not be exercised until the threshold is satisfied. Read SEC document |
| March 07, 2006 Filed Mar 9, 2006 22:10 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 1,862 | $22.73 | $42,323.26 |
DisclosureSEC source: 0000014272-06-000103 · sig521.xml · nonDerivative · entry 3 SIGAL ELLIOT · CIK 0001202294 · CSO & President PRI 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,184 F3 · shares: Shares withheld for payment of taxes. Read SEC document |
| March 07, 2006 Filed Mar 9, 2006 22:10 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantCommon Stock, $0.10 par value | 5,107 | $22.73 | $116,082.11 |
DisclosureSEC source: 0000014272-06-000103 · sig521.xml · nonDerivative · entry 2 SIGAL ELLIOT · CIK 0001202294 · CSO & President PRI 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 188,046 F2 · shares: Consists of shares earned as long-term performance awards under the 2002 Stock Incentive Plan. Read SEC document |
| March 07, 2006 Filed Mar 9, 2006 22:10 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantCommon Stock, $0.10 par value | 23,000 | $22.73 | $522,790.00 |
DisclosureSEC source: 0000014272-06-000103 · sig521.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · CSO & President PRI 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,939 F1 · shares: Shares consist of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date. Read SEC document |
| March 01, 2006 Filed Mar 2, 2006 19:23 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 3,871 | $22.94 | $88,800.74 |
DisclosureSEC source: 0000014272-06-000061 · sig513.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · CSO & President PRI 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,939 F1 · shares: Shares withheld for payment of taxes upon vesting of restricted stock. F2 · balance_after: Includes shares of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date. Read SEC document |
| February 21, 2006 Filed Feb 22, 2006 22:00 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 1,466 | $23.09 | $33,849.94 |
DisclosureSEC source: 0000014272-06-000051 · sig507.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · CSO & President PRI 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,810 F1 · shares: Shares withheld for payment of taxes upon vesting of restricted stock. F2 · balance_after: Includes restricted stock units with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date. Read SEC document |
| November 01, 2005 Filed Nov 2, 2005 19:44 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 3,871 | $21.12 | $81,755.52 |
DisclosureSEC source: 0000014272-05-000192 · sig464.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · CSO & President PRI 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,276 F1 · shares: Shares withheld for payment of taxes upon vesting of restricted stock. Read SEC document |
| September 20, 2005 Filed Sep 21, 2005 19:31 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantCommon Stock, $0.10 par value | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-05-000163 · sig439.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · CSO & President PRI 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,147 F1 · shares: Shares consist of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date. Read SEC document |
| March 01, 2005 Filed Mar 3, 2005 22:34 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantExecutive Option (right to buy) · Derivative | 103,500 | $0.00 Strike: $25.45 | $0.00 |
DisclosureSEC source: 0000014272-05-000075 · sig370.xml · derivative · entry 4 SIGAL ELLIOT · CIK 0001202294 · SVP, Global Clin & Pharm Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,500 Underlying: Common Stock, $0.10 par value · 103,500 shares Expires 2015-02-28 F4 · derivative.exercise_date: Option is not exercisable until the earlier of (i) the closing share price of common stock achieving a price of at least 15% above the option grant price and remaining at that price for seven consecutive trading days or (ii) the ninth anniversary of the grant date. Shares underlying option vest 25% a year, on a cumulative basis, commencing one year after the date of grant. Read SEC document |
| March 01, 2005 Filed Mar 3, 2005 22:34 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantCommon Stock, $0.10 par value | 17,250 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-05-000075 · sig370.xml · nonDerivative · entry 2 SIGAL ELLIOT · CIK 0001202294 · SVP, Global Clin & Pharm Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 119,147 F2 · shares: Shares consist of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date. Read SEC document |
| March 01, 2005 Filed Mar 3, 2005 22:34 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 3,038 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-05-000075 · sig370.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · SVP, Global Clin & Pharm Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,897 F1 · shares: Shares withheld for payment of taxes upon vesting of restricted stock. Read SEC document |
| February 22, 2005 Filed Feb 24, 2005 16:31 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 1,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-05-000045 · sig353.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · SVP, Global Clin & Pharm Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,935 F1 · shares: Shares withheld for payment of taxes upon vesting of restricted stock. Read SEC document |
| August 02, 2004 Filed Aug 3, 2004 20:14 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 939 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-04-000160 · sig297.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · SVP, Global Clin & Pharm Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,085 F1 · shares: Shares withheld for payment of taxes upon vesting of restricted stock. F2 · balance_after: Includes shares of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date. Read SEC document |
| March 15, 2004 Filed Mar 17, 2004 15:37 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantDeferred Share Units · Derivative | 8,519.84 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000014272-04-000083 · sig239.xml · derivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · SVP, Global Clin & Pharm Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,148.81 Underlying: Common Stock, $0.10 par value · 8,519.84 shares Expires not disclosed F1 · shares: Consists of deferred share units accrued under the 1997 Performance Incentive Plan. F2 · derivative.exercise_date: Deferred share units are settled in shares of stock either in one lump sum payment or in installments upon the employee's termination. F2 · derivative.expiration_date: Deferred share units are settled in shares of stock either in one lump sum payment or in installments upon the employee's termination. Read SEC document |
| March 02, 2004 Filed Mar 4, 2004 22:25 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantOption (right to buy) · Derivative | 48,333 | $0.00 Strike: $28.11 | $0.00 |
DisclosureSEC source: 0000014272-04-000078 · sig228.xml · derivative · entry 3 SIGAL ELLIOT · CIK 0001202294 · SVP, Global Clin & Pharm Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,333 Underlying: Common Stock, $0.10 par value · 48,333 shares Expires 2014-03-01 F3 · derivative.exercise_date: Exercisable as to 25% of the shares annually, on a cumulative basis, commencing one year after the date of grant. Read SEC document |
| March 02, 2004 Filed Mar 4, 2004 22:25 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantCommon Stock, $0.10 par value | 8,056 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-04-000078 · sig228.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · SVP, Global Clin & Pharm Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,024 F1 · shares: Shares consist of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date. Read SEC document |
| February 20, 2004 Filed Feb 23, 2004 21:52 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 1,056 | $28.41 | $30,000.96 |
DisclosureSEC source: 0000014272-04-000045 · sig212.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · SVP, Global Clin & Pharm Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,968 F1 · kind: Shares withheld for payment of taxes upon vesting of restricted stock. Read SEC document |
| September 10, 2003 Filed Sep 12, 2003 19:38 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | GrantCommon Stock, $0.10 par value | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-03-000036 · sig157.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · SVP, Global Clin & Pharm Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,024 F1 · shares: Shares consist of restricted stock with one-third vesting on each of the third, fourth and fifth anniversaries of the grant date. Read SEC document |
| August 01, 2003 Filed Aug 4, 2003 19:53 UTC | BRISTOL MYERS SQUIBB CO (BMY) · Entity 1662 | Tax withholdingCommon Stock, $0.10 par value | 1,219 | $0.00 | $0.00 |
DisclosureSEC source: 0000014272-03-000020 · sig150.xml · nonDerivative · entry 1 SIGAL ELLIOT · CIK 0001202294 · SVP, Global Clin & Pharm Dev 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,024 F1 · kind: Shares withheld for payment of taxes upon vesting of restricted stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.